Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Terpyridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.86 |
| ▸ | TP53 | P04637 | 4/20 | 0.86 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.86 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.86 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.86 |
| ▸ | CCR1 | P32246 | 3/20 | 0.86 |
| ▸ | CCR5 | P51681 | 3/20 | 0.86 |
| ▸ | CCR8 | P51685 | 3/20 | 0.86 |
| ▸ | LMNA | P02545 | 3/20 | 0.86 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.86 |
| ▸ | HTT | P42858 | 2/20 | 0.86 |
| ▸ | ALPL | P05186 | 2/20 | 0.86 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.86 |
| ▸ | ALPI | P09923 | 1/20 | 0.86 |
| ▸ | ALPG | P10696 | 1/20 | 0.86 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.86 |
| ▸ | METAP1 | P53582 | 2/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Terpyridine SCHEMBL2531483 | 0.98 | KDM4E (0.82) | KDM4ETP53ALOX15L3MBTL1SMN1; SMN2 | |
| Terpyridine SCHEMBL57442 | 0.93 | KDM4E (1.00) | KDM4ETP53ALOX15L3MBTL1SMN1; SMN2 | |
| Terpyridine SCHEMBL29357603 | 0.93 | KDM4E (1.00) | KDM4ETP53ALOX15L3MBTL1SMN1; SMN2 | |
| SCHEMBL30172832 | 0.93 | KDM4E (1.00) | KDM4ETP53ALOX15L3MBTL1SMN1; SMN2 | |
| SCHEMBL7964803 | 0.93 | KDM4E (1.00) | KDM4ETP53ALOX15L3MBTL1SMN1; SMN2 | |
| Terpyridine SCHEMBL7546808 | 0.91 | KDM4E (0.86) | KDM4ETP53ALOX15L3MBTL1SMN1; SMN2 | |
| Terpyridine SCHEMBL3150051 | 0.90 | KDM4E (0.95) | KDM4ETP53ALOX15L3MBTL1SMN1; SMN2 | |
| Terpyridine SCHEMBL1616654 | 0.90 | KDM4E (0.95) | KDM4ETP53ALOX15L3MBTL1SMN1; SMN2 | |
| Terpyridine SCHEMBL7112915 | 0.90 | KDM4E (0.95) | KDM4ETP53ALOX15L3MBTL1SMN1; SMN2 | |
| Terpyridine SCHEMBL5899140 | 0.90 | KDM4E (0.95) | KDM4ETP53ALOX15L3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3995492-B1 | A TWO-STEP PROCESS FOR PREPARING 3-SUBSTITUTED PHENYLALKYLAMINES | SpecGx LLC (US) | 2024-05-29 | — | — | EP | disclosed |
| EP-3166923-B1 | PROCESS FOR PREPARING SUBSTITUTED PHENYLALKANES | SpecGx LLC (US) | 2023-03-15 | — | — | EP | disclosed |
| EP-3995492-A1 | A TWO-STEP PROCESS FOR PREPARING 3-SUBSTITUTED PHENYLALKYLAMINES | SpecGx LLC (US) | 2022-05-11 | — | — | EP | disclosed |
| EP-3319941-B1 | A TWO-STEP PROCESS FOR PREPARING 3-SUBSTITUTED PHENYLALKYLAMINES | SpecGx LLC (US) | 2021-12-29 | — | — | EP | disclosed |
| US-9914695-B2 | Two-step process for preparing 3-substituted phenylalkylamines | MALLINCKRODT LLC (US) | 2018-03-13 | — | — | US | disclosed |
| US-9556108-B2 | Process for preparing substituted phenylalkanes | MALLINCKRODT LLC (US) | 2017-01-31 | — | — | US | disclosed |
| US-20170008832-A1 | TWO-STEP PROCESS FOR PREPARING 3-SUBSTITUTED PHENYLALKYLAMINES | MALLINCKRODT ENTERPRISES LLC | 2017-01-12 | — | — | US | disclosed |
| US-20160009635-A1 | PROCESS FOR PREPARING SUBSTITUTED PHENYLALKANES | MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY | 2016-01-14 | — | — | US | disclosed |
| US-8293938-B2 | Alkylphosphonous acids, salts and esters, methods for the production thereof, and use of the same | CLARIANT FINANCE (BVI) LIMITED (VG) | 2012-10-23 | — | — | US | disclosed |
| US-20100190901-A1 | Alkylphosphonous Acids, Salts and Esters, Methods for the Production Thereof, and Use of the Same | CLARIANT FINANCE (BVI) LIMITED (VG) | 2010-07-29 | — | — | US | disclosed |
| EP-0885233-B1 | TERPYRIDINE-PLATINUM(II) COMPLEXES | ISIS INNOVATION (GB) | 2002-06-19 | — | — | EP | disclosed |
| US-20020013306-A1 | TERPYRIDINE-PLATINUM(II) COMPLEXES | ISIS INNOVATION LIMITED (GB) | 2002-01-31 | — | — | US | disclosed |
| EP-1164138-A1 | Terpyridine-platinum (II) complexes | ISIS INNOVATION LIMITED (GB) | 2001-12-19 | — | — | EP | disclosed |
| EP-1155025-A1 | PLATINUM (II) COMPOUNDS | ISIS INNOVATION LIMITED (GB) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000050431-A1 | PLATINUM (II) COMPOUNDS | ISIS INNOVATION LIMITED (GB) | 2000-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009635-A1 | PROCESS FOR PREPARING SUBSTITUTED PHENYLALKANES | CYP2E1, CYP1B1, CYP4B1 | KDM4E 488/4885TP53 4748/4885ALOX15 648/4885 |
| US-20170008832-A1 | TWO-STEP PROCESS FOR PREPARING 3-SUBSTITUTED PHENYLALKYLAMINES | PNMT, CYP1B1, UGT2B7 | KDM4E 618/4885TP53 4836/4885ALOX15 2384/4885 |
| US-20020013306-A1 | TERPYRIDINE-PLATINUM(II) COMPLEXES | TOP2A, TOP1, TOP2B | KDM4E 4584/4885TP53 682/4885ALOX15 2396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.